Replies to post #22262 on Humanigen Inc (fka HGENQ)

[jb128]

This is the stuff I’ve been waiting for!

[eom7]

2103 ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

https://ash.confex.com/ash/2020/webprogram/Paper135988.html

[eom7]

Humanigen “should not be thought of as a ‘COVID company,’” Roth analyst Tony Butler wrote in a late September report. “But, in fact, there is evidence in the scientific literature that [lenzilumab] may slow or impede the progression of COVID pneumonia.” He cited results from the small Mayo cohort showing such patients get out of the hospital much quicker when treated with lenzilumab than others. Referring to a 1971 song by The Doors, Butler called Humanigen a “rider on the [cytokine] storm,” with COVID-19 portraying “the hitchhiker wandering aimlessly from town to town, the killer on the road. We all wonder when and exactly how we strangle SARS-CoV-2.”

Maybe this will got us the $25 target Butler gave HGEN sans Covid.